Literature DB >> 15742441

Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection.

Douglas Lienesch1, Robert Morris, Allan Metzger, Paige Debuys, Kenneth Sherman.   

Abstract

OBJECTIVE: The increased prevalence of rheumatoid factor (RF) in patients with chronic hepatitis C virus (HCV) infection markedly diminishes the diagnostic specificity of serum rheumatoid factor (RF) for rheumatoid arthritis (RA) in patients with HCV. Cyclic citrullinated peptide (CCP) antibody, a highly specific biomarker for RA in the general population, may have better diagnostic utility for RA in the HCV population. To investigate if CCP antibody retains its specificity for RA in HCV infection, we determined the prevalence of CCP antibodies and examined the relationship between RF production and CCP antibody levels in a population of nonarthritic patients with chronic HCV infection.
METHODS: CCP antibody and IgM, IgG, and IgA RF isotypes were determined by ELISA in serum from nonarthritic patients with chronic HCV infection.
RESULTS: In a series of 50 HCV patients, IgG-RF, IgM-RF, and IgA-RF were detectable in 52%, 26%, and 14%, respectively, with a total seropositivity rate of 54%. Marginally elevated CCP antibody was detected in a single patient (2%). By regression analysis, serum levels of CCP antibodies did not correlate with RF levels.
CONCLUSION: In contrast to RF, CCP antibody is not increased in HCV infection. CCP antibody may have improved utility for the diagnosis of RA in this patient population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15742441

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  Antibodies to mutated citrullinated vimentin in patients with chronic hepatitis C virus genotype IV infection-related arthropathy.

Authors:  M Zehairy; E Soliman; A Daghaidy
Journal:  Rheumatol Int       Date:  2011-11-09       Impact factor: 2.631

2.  Serum rheumatoid factor is correlated with liver fibrosis in patients with chronic hepatitis B.

Authors:  Yusuf Coskun; Ilhami Yuksel
Journal:  Wien Klin Wochenschr       Date:  2020-09-14       Impact factor: 1.704

Review 3.  Antibodies against cyclic citrullinated peptides in infectious diseases--a systematic review.

Authors:  Isabella Lima; Mittermayer Santiago
Journal:  Clin Rheumatol       Date:  2010-08-05       Impact factor: 2.980

4.  Anti-cyclic citrullinated peptide and rheumatoid factor in patients with chronic hepatitis B and hepatitis B carriers.

Authors:  Ediz Dalkılıç; Mustafa Ferhat Öksüz; Ayşe Nur Tufan; Aysun Özbek; Ali Nizamoğlu; Mürside Esra Dolarslan; Belkıs Nihan Coşkun; Yavuz Pehlivan
Journal:  Eur J Rheumatol       Date:  2015-03-31

5.  Hepatitis C-related arthropathy: Diagnostic and treatment considerations.

Authors:  Nyingi M Kemmer; Kenneth E Sherman
Journal:  J Musculoskelet Med       Date:  2010-09

6.  Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection.

Authors:  Amy M Joseph
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

7.  Anti-cyclic citrullinated Peptide frequency in patients with chronic hepatitis C virus infection and effect of presence of systemic disease.

Authors:  Ayse Albayrak; Hakan Dursun; Muhammet Hamidullah Uyanik; Serkan Cerrah
Journal:  Eurasian J Med       Date:  2012-12

8.  Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia.

Authors:  Feng-Cheng Liu; You-Chen Chao; Tsung-Yun Hou; Hsiang-Cheng Chen; Rong-Yaun Shyu; Tsai-Yuan Hsieh; Chen-Hung Chen; Deh-Ming Chang; Jenn-Haung Lai
Journal:  Clin Rheumatol       Date:  2007-09-18       Impact factor: 2.980

9.  Positional cloning of the Igl genes controlling rheumatoid factor production and allergic bronchitis in rats.

Authors:  Carola Rintisch; Jacqueline Ameri; Peter Olofsson; Holger Luthman; Rikard Holmdahl
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-08       Impact factor: 11.205

10.  The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection.

Authors:  E Orge; A Cefle; Ayten Yazici; N Gürel-Polat; S Hulagu
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.